Molecular Partners AG (MOLN)

Market Cap	142.80M
Revenue (ttm)	n/a
Net Income (ttm)	-75.54M
Shares Out	37.40M
EPS (ttm)	-2.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,156
Open	4.105
Previous Close	4.120
Day's Range	3.990 - 4.105
52-Week Range	3.360 - 5.990
Beta	0.57
Analysts	Hold
Price Target	4.00 (-4.76%)
Earnings Date	Oct 30, 2025

About MOLN

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2021
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: MOLN
• Website: https://www.molecularpartners.com

Financial Performance

In 2024, Molecular Partners AG's revenue was 4.97 million, a decrease of -29.38% compared to the previous year's 7.04 million. Losses were -54.04 million, -12.81% less than in 2023.

Financial numbers in CHF

Analyst Summary

According to one analyst, the rating for MOLN stock is "Hold" and the 12-month stock price target is $4.0.

Price Target

$4.0

(-4.76% downside)

Analyst Consensus: Hold